badbehavior, do you know how stupid you sound? The game is almost over for you.
And nick has been talking like that ever since $6.50
You better work a little harder, you are starting to losing control of this thing.
I guess they need to hear the truth again. Shorts are working overtime today.
Hey Frank, What do you think? Market seems to like the change in CEO.
She looks like sharp marketing leadership.
J20, think of it as a possible front line defense. Imagine you have a strong family history of cancer, and Celldex has a therapy (1127) that has the effect of boosting the immune system, causing a vaccination boost like effect. Would you not want that therapy for you and your loved ones if it had no adverse long term adverse effects?
Maybe insurance companies would be willing to pay for the treatment, so as to avoid the cost of treating cancer at a later date.
Cheese, Celldex could be an 8 to 10billion company on 1127 alone. And that may be too conservative. The want of other companies to use 1127 to show greater efficacy of their own drugs is the Celldex trump card.
I am wondering if 1127 would be prescribed to healthy people at some point. As an immune boost against possible cancers.
The thing to remember about 1127, according to M, there are no current treatments that do what 1127 does with a safety profile that matches 1127. It is both safe and effective, and so can be used outside of university hospitals or major hospitals. 1127 has NO ADVERSE EFFECT TO DATE, and could be combined with a multitude of other treatments or alone.
He is attempting to do others (his friends) a favor, they have to keep the price down this week, next week his friends will write glowing stories of how Celldex is a screaming buy.
Anything to keep the SP down until options expiration. The way your article was written, riddled in contradiction, and missing most vast pipeline and good news, it's obvious you don't really believe your own negative slant. IMO
News Release Details
Halozyme Therapeutics Announces Executive Transitions
Helen Torley to assume role of President and CEO; Gregory I. Frost to lead Intrexon's Health Sector and will remain on Halozyme's Scientific Advisory Board
SAN DIEGO, Dec. 17, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that Helen Torley, M.B. Ch. B., M.R.C.P., will be joining Halozyme as President and Chief Executive Officer on January 6, 2014. She will also become a member of Halozyme's Board of Directors. Dr. Torley was most recently Executive Vice President and Chief Commercial Officer at Onyx Pharmaceuticals, a subsidiary of Amgen. Gregory I. Frost, Ph.D. is departing Halozyme for Intrexon (NYSE: XON), assuming the head of that company's Health Sector, and will continue to lead Halozyme's Scientific Advisory Board. Dr. Frost will join Intrexon effective January 6, 2014.
Precisely, and that repetition is why I think we can say Celldex does have at least some proof of Concept on CDX110, which many continue to suggest otherwise.
Yes, that's how I remember it as well. That's why I said the dark side. However, his quote sounds like progress. Its hard to admit error.
KY, within 3 years he will be completely debt free, own his vacation home, have so much cash he will need to open up new accounts in other banks, setting up trust funds for his grandchildren, and traveling the world while remembering your post with a smile on his face.
No dear, you where the one being bigoted. He was simply pulling your tail, as you would not shut up with the personal attacks.
So we are to move on until you start attacking again? Right.........
tpatten, did AF just come to the dark-side???? Thats a sure signal he and his buddies are now fully vested in
celldex, and we should expect a pending rise in the SP of Celldex. Next, we should expect Cramer to change his mind again, yelling BUY!, BUY! BUY!
For the record, I remain long, and suggest everyone buy as much as your portfolio allows.